0001144204-17-048089.txt : 20170914
0001144204-17-048089.hdr.sgml : 20170914
20170914190037
ACCESSION NUMBER: 0001144204-17-048089
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170912
FILED AS OF DATE: 20170914
DATE AS OF CHANGE: 20170914
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: O'Toole David D
CENTRAL INDEX KEY: 0001491140
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38193
FILM NUMBER: 171086573
MAIL ADDRESS:
STREET 1: 1640 MARENGO STREET
CITY: LOS ANGELES
STATE: CA
ZIP: 90033
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OPIANT PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001385508
STANDARD INDUSTRIAL CLASSIFICATION: METAL MINING [1000]
IRS NUMBER: 000000000
STATE OF INCORPORATION: NV
FISCAL YEAR END: 0731
BUSINESS ADDRESS:
STREET 1: 201 SANTA MONICA BOULEVARD
STREET 2: SUITE 500
CITY: SANTA MONICA
STATE: CA
ZIP: 90401
BUSINESS PHONE: (310) 598-5410
MAIL ADDRESS:
STREET 1: 201 SANTA MONICA BOULEVARD
STREET 2: SUITE 500
CITY: SANTA MONICA
STATE: CA
ZIP: 90401
FORMER COMPANY:
FORMER CONFORMED NAME: Lightlake Therapeutics Inc.
DATE OF NAME CHANGE: 20091009
FORMER COMPANY:
FORMER CONFORMED NAME: Madrona Ventures, Inc.
DATE OF NAME CHANGE: 20070108
4
1
v475189_4.xml
OWNERSHIP DOCUMENT
X0306
4
2017-09-12
0
0001385508
OPIANT PHARMACEUTICALS, INC.
OPNT
0001491140
O'Toole David D
C/O OPIANT PHARMACEUTICALS, INC.
201 SANTA MONICA BOULEVARD, SUITE 500
SANTA MONICA
CA
90401
0
1
0
0
Chief Financial Officer
Stock Option (right to buy)
36.00
2017-09-12
4
A
0
150000
0
A
2018-09-12
2027-09-11
Common Stock
150000
150000
D
On September 12, 2017, the reporting person was granted an option to purchase 150,000 shares of common stock. The option vests as follows: Twenty-five percent (25%) of the shares of common stock underlying the option shall vest on the one-year anniversary of the date of grant, and 2.083% of the shares of common stock underlying the option shall vest monthly thereafter, becoming fully vested on the four-year anniversary of the date of grant.
/s/ David D. O'Toole
2017-09-14